Cuiming Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cuiming Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Guiting He
Institute of Pathogenic Biology, Hengyang Medical College, University of South China; Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang, Hunan, China
4 shared publicationsHuanbing Long
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control
4 shared publicationsJiarong He
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control
4 shared publicationsAihua Lei
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control
2 shared publicationsNaiyu Zhang
Institute of Pathogenic Biology, Hengyang Medical College, University of South China; Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control , Hengyang, Hunan 421001 , People's Republic of China
2 shared publicationsPengxiao Feng
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1930950
A multi-epitope vaccine targeting Mycoplasma pneumoniae P1 adhesin and CARDS toxin confers synergistic protection by adhesion inhibition and toxin neutralization
Background: Mycoplasma pneumoniae (Mp) remains a major cause of community-acquired pneumonia in children and adolescents, and no vaccine against this pathogen is currently available. This study designed and evaluated P1Tx, a novel multi-epitope vaccine candidate derived from the immunodominant regions of the P1 adhesin and the community-acquired respiratory distress syndrome (CARDS) toxin. Methods: Immunoinformatics approaches were used to select immunodominant epitopes from the P1 adhesin and the CARDS toxin of Mp , which were assembled into a 263-amino acid chimeric construct designated P1Tx. The construct was expressed in Escherichia coli , and the recombinant protein was characterized for physicochemical properties and predicted structural stability. Its immunoreactivity was assessed using sera from Mp -infected patients. BALB/c mice received three subcutaneous immunizations with P1Tx, and humoral and cellular immune responses were evaluated by antibody endpoint titers and flow cytometric analysis of germinal center B cells and T cell subsets. The functional activity of immune sera was tested by measuring its capacity to block Mp adhesion to human bronchial epithelial cells and to neutralize CARDS toxin-induced cytotoxicity. Protective efficacy was assessed in mice challenged intranasally with the Mp M129 strain, with pulmonary bacterial burden and histopathological changes determined after challenge. Results: P1Tx displayed favorable physicochemical characteristics and structural stability and reacted strongly with sera from Mp -infected patients. Immunized mice developed high-titer, IgG1-dominant antibody responses (endpoint titers up to 1:50,000) accompanied by marked germinal center B cell expansion. Compared with the P1C subunit vaccine, P1Tx elicited substantially stronger cellular immunity, with significant expansion of CD4+ and CD8+ effector and memory T cell populations. Sera from P1Tx-immunized mice inhibited Mp adhesion to bronchial epithelial cells and neutralized CARDS toxin-mediated cytotoxicity in vitro. Following intranasal challenge, P1Tx-immunized mice showed a 98.5% reduction in pulmonary bacterial burden and a 52.4% reduction in lung histopathological scores relative to the PBS group. Conclusions: P1Tx confers protection against Mp infection through complementary mechanisms of adhesion blockade and toxin neutralization, supporting its further development as a vaccine candidate for the prevention of Mp infection.
- 22 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1930950
Open AccessA multi-epitope vaccine targeting Mycoplasma pneumoniae P1 adhesin and CARDS toxin confers synergistic protection by adhesion inhibition and toxin neutralization
Background: Mycoplasma pneumoniae (Mp) remains a major cause of community-acquired pneumonia in children and adolescents, and no vaccine against this pathogen is currently available. This study designed and evaluated P1Tx, a novel multi-epitope vaccine candidate derived from the immunodominant regions of the P1 adhesin and the community-acquired respiratory distress syndrome (CARDS) toxin. Methods: Immunoinformatics approaches were used to select immunodominant epitopes from the P1 adhesin and the CARDS toxin of Mp , which were assembled into a 263-amino acid chimeric construct designated P1Tx. The construct was expressed in Escherichia coli , and the recombinant protein was characterized for physicochemical properties and predicted structural stability. Its immunoreactivity was assessed using sera from Mp -infected patients. BALB/c mice received three subcutaneous immunizations with P1Tx, and humoral and cellular immune responses were evaluated by antibody endpoint titers and flow cytometric analysis of germinal center B cells and T cell subsets. The functional activity of immune sera was tested by measuring its capacity to block Mp adhesion to human bronchial epithelial cells and to neutralize CARDS toxin-induced cytotoxicity. Protective efficacy was assessed in mice challenged intranasally with the Mp M129 strain, with pulmonary bacterial burden and histopathological changes determined after challenge. Results: P1Tx displayed favorable physicochemical characteristics and structural stability and reacted strongly with sera from Mp -infected patients. Immunized mice developed high-titer, IgG1-dominant antibody responses (endpoint titers up to 1:50,000) accompanied by marked germinal center B cell expansion. Compared with the P1C subunit vaccine, P1Tx elicited substantially stronger cellular immunity, with significant expansion of CD4+ and CD8+ effector and memory T cell populations. Sera from P1Tx-immunized mice inhibited Mp adhesion to bronchial epithelial cells and neutralized CARDS toxin-mediated cytotoxicity in vitro. Following intranasal challenge, P1Tx-immunized mice showed a 98.5% reduction in pulmonary bacterial burden and a 52.4% reduction in lung histopathological scores relative to the PBS group. Conclusions: P1Tx confers protection against Mp infection through complementary mechanisms of adhesion blockade and toxin neutralization, supporting its further development as a vaccine candidate for the prevention of Mp infection.
- Open Access
- 25 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312318
The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice
Mycoplasma pneumoniae represents one of the significant etiologies of community-acquired pneumonia in pediatric patients. However, clinical treatment of M. pneumoniae infection in children has encountered challenges due to the escalating resistance to quinolones. Numerous studies have highlighted the potential of probiotic lactobacillus administration in boosting immune responses to bacterial and viral respiratory infections. In this study, the protective efficacy of pre-oral administration of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, Lactiplantibacillus plantarum NCIMB 8826, L. plantarum S1 or L. plantarum S2 was evaluated in the BALB/c mice model; it was observed that among these five strains of lactobacillus, the supplementation of LGG exhibited the most significant protective effect against M. pneumoniae infection. Moreover, when administered orally, both live LGG and heat-inactivated LGG have demonstrated efficacy in reducing the burden of M. pneumoniae in the lungs and alleviating pulmonary inflammation. Oral supplementation with LGG resulted in the inhibition of neutrophil recruitment into the lungs and increased recruitment of alveolar macrophages in M. pneumoniae-infected mice. Additionally, LGG supplementation led to increased production of IL-10 and secretory IgA (sIgA), while suppressing the levels of IL-1β, IL-6, IL-17A, and TNF-α in the lungs of mice infected with M. pneumoniae. The data suggests that supplementation with LGG can modulate immune responses, decrease pathogen load, and alleviate inflammatory injury in the lungs of M. pneumoniae-infected mice.
- 25 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312318
Open AccessThe protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice
Mycoplasma pneumoniae represents one of the significant etiologies of community-acquired pneumonia in pediatric patients. However, clinical treatment of M. pneumoniae infection in children has encountered challenges due to the escalating resistance to quinolones. Numerous studies have highlighted the potential of probiotic lactobacillus administration in boosting immune responses to bacterial and viral respiratory infections. In this study, the protective efficacy of pre-oral administration of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, Lactiplantibacillus plantarum NCIMB 8826, L. plantarum S1 or L. plantarum S2 was evaluated in the BALB/c mice model; it was observed that among these five strains of lactobacillus, the supplementation of LGG exhibited the most significant protective effect against M. pneumoniae infection. Moreover, when administered orally, both live LGG and heat-inactivated LGG have demonstrated efficacy in reducing the burden of M. pneumoniae in the lungs and alleviating pulmonary inflammation. Oral supplementation with LGG resulted in the inhibition of neutrophil recruitment into the lungs and increased recruitment of alveolar macrophages in M. pneumoniae-infected mice. Additionally, LGG supplementation led to increased production of IL-10 and secretory IgA (sIgA), while suppressing the levels of IL-1β, IL-6, IL-17A, and TNF-α in the lungs of mice infected with M. pneumoniae. The data suggests that supplementation with LGG can modulate immune responses, decrease pathogen load, and alleviate inflammatory injury in the lungs of M. pneumoniae-infected mice.
- 5 August 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 2229-2250
The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development
Lactiplantibacillus plantarum (previously known as Lactobacillus plantarum) is a lactic acid bacterium that exists in various niches. L. plantarum is a food-grade microorganism that is commonly considered a safe and beneficial microorganism. It is widely used in food fermentation, agricultural enhancement, and environmental protection. L. plantarum is also part of the normal flora that can regulate the intestinal microflora and promote intestinal health. Some strains of L. plantarum are powerful probiotics that induce and modulate the innate and adaptive immune responses. Due to its outstanding immunoregulatory capacities, an increasing number of studies have examined the use of probiotic L. plantarum strains as natural immune adjuvants or alternative live vaccine carriers. The present review summarizes the main immunomodulatory characteristics of L. plantarum and discusses the preliminary immunological effects of L. plantarum as a vaccine adjuvant and delivery carrier. Different methods for improving the immune capacities of recombinant vector vaccines are also discussed.
- 5 August 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 2229-2250
The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development
Lactiplantibacillus plantarum (previously known as Lactobacillus plantarum) is a lactic acid bacterium that exists in various niches. L. plantarum is a food-grade microorganism that is commonly considered a safe and beneficial microorganism. It is widely used in food fermentation, agricultural enhancement, and environmental protection. L. plantarum is also part of the normal flora that can regulate the intestinal microflora and promote intestinal health. Some strains of L. plantarum are powerful probiotics that induce and modulate the innate and adaptive immune responses. Due to its outstanding immunoregulatory capacities, an increasing number of studies have examined the use of probiotic L. plantarum strains as natural immune adjuvants or alternative live vaccine carriers. The present review summarizes the main immunomodulatory characteristics of L. plantarum and discusses the preliminary immunological effects of L. plantarum as a vaccine adjuvant and delivery carrier. Different methods for improving the immune capacities of recombinant vector vaccines are also discussed.
- 2 February 2023
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (3)
Lacticaseibacillus caseiCNRZ1874 supplementation promotes M1 alveolar macrophage activation and attenuatesMycoplasma pneumoniaepneumonia
To evaluate the protective effect of intestinal supplementation with Lacticaseibacillus casei CNRZ1874 on the inflammatory response induced by Mycoplasma pneumoniae in C57BL/6J mice, and provide a potential strategy for alleviating M.pneumoniae pneumonia. C57BL/6J mice were gavaged with L. casei CNRZ1874 or PBS for 7 consecutive days, and then infected with M.pneumoniae on day 8. Treatment with L. casei CNRZ1874 significantly reduced M.pneumoniae loads in the lungs and alleviated the lung inflammation on day 3 and day 10 after pathogen infection. Importantly, oral administration with L. casei CNRZ1874 promoted M1 alveolar macrophages activation as evidenced by increased expression of iNOS, TNF-α and CXCL1, while inhibited M2 alveolar macrophages activation as the expression of Arg1 and Chi3l3 were significantly decreased. In consistent with the M1 alveolar macrophages activation and enhanced mycoplasma clearance, the level of TNF-α was increased while the level of IL-4 was decreased in lung tissue from the L. casei CNRZ1874 group compared with the control group. However, oral administration with L. casei CNRZ1874 may not influence adaptive immunity induced by M.pneumoniae as evaluated by M.pneumoniae specific antibodies and T cells responses in spleen. Intestinal supplementation with L. casei CNRZ1874 can promote M1 alveolar macrophages activation, which contributes to the clearance of M. pneumoniae and attenuation of M.pneumoniae pneumonia.
- 2 February 2023
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (3)
Lacticaseibacillus caseiCNRZ1874 supplementation promotes M1 alveolar macrophage activation and attenuatesMycoplasma pneumoniaepneumonia
To evaluate the protective effect of intestinal supplementation with Lacticaseibacillus casei CNRZ1874 on the inflammatory response induced by Mycoplasma pneumoniae in C57BL/6J mice, and provide a potential strategy for alleviating M.pneumoniae pneumonia. C57BL/6J mice were gavaged with L. casei CNRZ1874 or PBS for 7 consecutive days, and then infected with M.pneumoniae on day 8. Treatment with L. casei CNRZ1874 significantly reduced M.pneumoniae loads in the lungs and alleviated the lung inflammation on day 3 and day 10 after pathogen infection. Importantly, oral administration with L. casei CNRZ1874 promoted M1 alveolar macrophages activation as evidenced by increased expression of iNOS, TNF-α and CXCL1, while inhibited M2 alveolar macrophages activation as the expression of Arg1 and Chi3l3 were significantly decreased. In consistent with the M1 alveolar macrophages activation and enhanced mycoplasma clearance, the level of TNF-α was increased while the level of IL-4 was decreased in lung tissue from the L. casei CNRZ1874 group compared with the control group. However, oral administration with L. casei CNRZ1874 may not influence adaptive immunity induced by M.pneumoniae as evaluated by M.pneumoniae specific antibodies and T cells responses in spleen. Intestinal supplementation with L. casei CNRZ1874 can promote M1 alveolar macrophages activation, which contributes to the clearance of M. pneumoniae and attenuation of M.pneumoniae pneumonia.
- Open Access
- 31 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 908010
The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases
Respiratory diseases cause a high incidence and mortality worldwide. As a natural immunobiotic, Lactobacillus has excellent immunomodulatory ability. Administration of some Lactobacillus species can alleviate the symptoms of respiratory diseases such as respiratory tract infections, asthma, lung cancer and cystic fibrosis in animal studies and clinical trials. The beneficial effect of Lactobacillus on the respiratory tract is strain dependent. Moreover, the efficacy of Lactobacillus may be affected by many factors, such as bacteria dose, timing and host background. Here, we summarized the beneficial effect of administered Lactobacillus on common respiratory diseases with a focus on the mechanism and safety of Lactobacillus in regulating respiratory immunity.
- 31 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 908010
Open AccessThe Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases
Respiratory diseases cause a high incidence and mortality worldwide. As a natural immunobiotic, Lactobacillus has excellent immunomodulatory ability. Administration of some Lactobacillus species can alleviate the symptoms of respiratory diseases such as respiratory tract infections, asthma, lung cancer and cystic fibrosis in animal studies and clinical trials. The beneficial effect of Lactobacillus on the respiratory tract is strain dependent. Moreover, the efficacy of Lactobacillus may be affected by many factors, such as bacteria dose, timing and host background. Here, we summarized the beneficial effect of administered Lactobacillus on common respiratory diseases with a focus on the mechanism and safety of Lactobacillus in regulating respiratory immunity.
- Open Access
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 9431-9445
Up-Conversion Luminescent Nanoparticles for Molecular Imaging, Cancer Diagnosis and Treatment
In the past few years, we have witnessed great development and application potential of various up-conversion luminescent nanoparticles (UCNPs) in the nanomedicine field. Based on the unique luminescent mechanism of UCNPs and the distinguishable features of cancer biomarkers and the microenvironment, an increasing number of smart UCNPs nanoprobes have been designed and widely applied to molecular imaging, cancer diagnosis, and treatment. Considerable technological success has been achieved, but the main obstacles to oncology nanomedicine is becoming an incomplete understanding of nano–bio interactions, the challenges regarding chemistry manufacturing and controls required for clinical translation and so on. This review highlights the progress of the design principles, synthesis and surface functionalization preparation, underlying applications and challenges of UCNPs-based probes for cancer bioimaging, diagnosis and treatment that capitalize on our growing understanding of tumor biology and smart nano-devices for accelerating the commercialization of UCNPs.
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 9431-9445
Open AccessUp-Conversion Luminescent Nanoparticles for Molecular Imaging, Cancer Diagnosis and Treatment
In the past few years, we have witnessed great development and application potential of various up-conversion luminescent nanoparticles (UCNPs) in the nanomedicine field. Based on the unique luminescent mechanism of UCNPs and the distinguishable features of cancer biomarkers and the microenvironment, an increasing number of smart UCNPs nanoprobes have been designed and widely applied to molecular imaging, cancer diagnosis, and treatment. Considerable technological success has been achieved, but the main obstacles to oncology nanomedicine is becoming an incomplete understanding of nano–bio interactions, the challenges regarding chemistry manufacturing and controls required for clinical translation and so on. This review highlights the progress of the design principles, synthesis and surface functionalization preparation, underlying applications and challenges of UCNPs-based probes for cancer bioimaging, diagnosis and treatment that capitalize on our growing understanding of tumor biology and smart nano-devices for accelerating the commercialization of UCNPs.